GreenLight Biosciences (GRNA) Form 3 GreenLight Biosciences Holdings, PBC / Pharma S.L. Insud ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Insud Pharma S.L.

(Last) (First) (Middle)

CALLE DE MANUEL POMBO ANGULO,

NO. 28, 3RD FLOOR

(Street)

MADRID U3 28050

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/29/2023

3. Issuer Name and Ticker or Trading Symbol
GreenLight Biosciences Holdings, PBC [ GRNA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
Member of a 10% owner group

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.0001 per share	2,551,020	D(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person is the owner of record of all such shares of Common Stock.

Remarks:

As discussed in the Reporting Person's Schedule 13D filed on June 8, 2023, a result of the entry of the Reporting Person and other stockholders of the Issuer (the "Rollover Stockholders") into contribution and exchange agreements, dated May 29, 2023, between each of them and SW ParentCo, Inc., a Delaware corporation, in connection with the Issuer's signed merger agreement, the Reporting Person may be deemed to be member, along with the other Rollover Stockholders, of a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which "group" collectively owns 120,521,038 shares of the Issuer's outstanding Common Stock. The Common Stock reported herein, which is the only Common Stock in which the Reporting Person has reportable pecuniary interest, does not include any Common Stock which may be beneficially owned by any of the other parties to documents relating to the merger agreement not deemed to be in the "group." The Rollover Stockholders in the "group" other than the Reporting Person herein have been notified by the Issuer that such individuals and/or entities may beneficially own certain Common Stock and need to file separate beneficial ownership reports with the SEC related thereto. Neither the filing of this Form 3 nor any of its contents, however, shall be deemed to constitute an admission by the Reporting Person that it is the beneficial owner of any of the Common Stock beneficially owned in the aggregate by other members of the "group" and their respective affiliates for purposes of Section 13(d)(3) of the Exchange Act or for any other purpose, and such beneficial ownership and pecuniary interest is expressly disclaimed.

	/s/ Ana Mondedeu Insunza, as Associate General Counsel and Secretary of Insud Pharma, S.L.	06/08/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.